Loading stock…

Edwards Lifesciences Corporation (EW) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Edwards Lifesciences Corporation

EWMarket cap $49BPrice $85.8

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Manufactures heart valves and hemodynamic monitoring systems for cardiovascular surgeries. Their artificial heart valves have been implanted in over 15 million patients worldwide, making cardiac procedures safer and extending lives globally.

In Bastion Portfolios?

52W Return+15%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+11%7

Revenue Forecast

Rev CAGR (1y)+11%7

Rev CAGR (3y)+10%7

Rev CAGR (5y)+10%7

Earnings Forecast

EPS Growth Y+1+64%10

EPS Growth Y+2+12%7

EPS Growth Y+3+12%7

Quality

Margins

EBIT Margin28%9

Net Income Margin15%7

Free Cash Flow Margin22%8

Debt

Net Debt/EBITDA-1.810

Efficiency

ROE9%4

ROA7%7

Earnings Stability55

GEAR+VERY STRONG87

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)282

P/E Ratio (Forward 3y)232

P/BV4.73

EV Multiples

EV/EBITDA Fwd222

EV/EBIT Fwd233

Yield

Free Cash Flow Yield2.9%5

Dividend Yieldna–

Momentum

Short term

1 month return-1%7

3 month return-8%4

YTD return+1%5

Mid term

Price vs 52wHigh89%8

1 year return+13%6

Long term

3 year return+16%4

5 year return-21%2

Risk Shield

Price Risk

Beta0.58

Volatility25%8

Free Cash Flow

Free Cash Flow Margin22%8

Free Cash Flow Yield2.9%5

Quality

ROCE15%8

Earnings Stability55

Net Debt/EBITDA-1.810

02Growth

Is it actually growing, and how fast?

EWEdwards Lifesciences

Revenue FY25$6.1B

GROWTH RATING↗

STRONG70 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+11%7

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+64%10

EPS growth, FY27E+12%7

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 70% of companies worldwide.

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 10%/yr.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 12%/yr vs revenue 10%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE44 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return-8%4

YTD return+1%5

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+13%6

3-year return+16%4

5-year return-21%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 13% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (-1%).

WATCH

Returns sit at the market level over three months (-8%) and so far this year (+1%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+16% over three years and -21% over five), behind 70% of the market.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Edwards Life. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

EWEdwards Lifesciences

Revenue FY25$6.1B

GROWTH RATING↗

STRONG70 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+11%7

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+64%10

EPS growth, FY27E+12%7

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 70% of companies worldwide.

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 10%/yr.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 12%/yr vs revenue 10%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE44 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return-8%4

YTD return+1%5

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+13%6

3-year return+16%4

5-year return-21%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 13% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (-1%).

WATCH

Returns sit at the market level over three months (-8%) and so far this year (+1%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+16% over three years and -21% over five), behind 70% of the market.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Edwards Life. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community